TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01007643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii Fit (TM) Interactive Video Game
Description: Use of interactive video game exercise program on a daily basis focusing on quadriceps and hamstring flexibility along with VMO strengthening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Home Exercise Program
Description: Completion of daily home exercise program for quadriceps and hamstring flexibility and VMO strengthening.
Study: NCT03605173

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: free vitamin d test
Description: using the patient's blood serum ELISA test for free vitamin d can be performed

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: total vitamin d
Description: routinely measured from serum
Study: NCT02037633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca compartment block
Description: Fascia iliaca compartment block using ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Study: NCT03190447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquacel Surgical®
Description: Measuring the skin integrity with each dressing and the patient satisfaction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Border post-op®
Description: Measuring the skin integrity with each dressing and the patient satisfaction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opsite post-op visible®
Description: Measuring the skin integrity with each dressing and the patient satisfaction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urgotul ABSORB border silicona®
Description: Measuring the skin integrity with each dressing and the patient satisfaction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dressing
Description: Measuring the skin integrity with each dressing and the patient satisfaction
Study: NCT00640133

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active DBS
Description: In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant. After a post-operative rest, participants will receive immediate DBS treatment throughout.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active DBS
Description: In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant. After a post-operative rest, participants will receive immediate DBS treatment throughout.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham DBS
Description: In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will mimic adjusting the settings of the electrical stimulation. After a post-operative rest, participants will receive DBS treatment after a delay of several months. Afterwards, all participants will receive open-label long-term DBS.
Study: NCT03086525

Intervention type: OTHER
Intervention: Diagnosis/Prognosis
Description: The present study will be a prospective observational study of 4 years that will be carried out between September 2017 and September 2020 at the University of Malaga. Several questionnaires assessing different beliefs associated with pain will be administered to participants. The results will be evaluated at baseline (t1) and in 4 follow-ups (at 12 (t2), 24 (t3), 36 (t4) and 48 (t5) months.
Study: NCT00472160

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Invasive Ventilation
Description: Non Invasive Ventilation
Study: NCT03980080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE-127
Description: mAb antagonist to CD127 receptor (or IL-7Rα)~Group 8-9~2 escalating dose level groups IV
Study: NCT02153086

Intervention type: DRUG
Intervention: Ramelteon
Description: Ramelteon tablets 8 mg
Study: NCT03840018

Intervention type: OTHER
Group type: OTHER
Intervention: Letter by post to patients
Description: Patients received an informative letter by post, in which their doctor invited them to seek an appointment for a medication review
Study: NCT02040324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask with gastric access

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Study: NCT03303963

Intervention type: DIAGNOSTIC_TEST
Intervention: Deeplex test, MolBio TrueNat for 2nd line, GeneXpert 2nd line
Description: Improvement of the diagnosis of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to diagnose Tuberculosis resistance to 1st and 2nd line drugs through novel molecular multiplex assays (Study 1) by:~* Validating the Deeplex test and establish a network for shipment of sputum samples in ethanol to regional reference laboratories (Study 1 - phase 1)~* Validating the Molbio Truenat test as a point of care test (Study 1 - phase 2)~* Validating the Cepheid GeneXpert 2nd line cartridge at the district level (Study 1 -phase2)

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value, pre-rRNA synthesis
Description: Improvement of the management of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to set up alternative culture-free approaches for the monitoring of patients' response to Multi Drug Resistant-Tuberculosis treatment (Study 2), with:~* FDA microscopy~* Measurement of bacterial load by following Cycle threshold (Ct) values in GeneXpert Mycobacterium tuberculosis/Rifampicin~* Measurement of pre-rRNA synthesis
Study: NCT03860649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: 24 sessions will be held twice a week, with each session taking an average of 60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jogging
Description: 24 sessions will be held twice a week, with each session taking an average of 60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: 24 sessions will be held twice a week, with each session taking an average of 60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Training
Description: 24 sessions will be held twice a week, with each session taking an average of 60 minutes.
Study: NCT02651207

Intervention type: OTHER
Intervention: Questionnaire based study looking at pain scores felt by patients either having a lidocaine injection or ethyl chloride spray prior to insertion of a contraceptive implant

Intervention type: OTHER
Intervention: Questionnaire based study looking at pain scores felt by patients either having a lidocaine injection or ethyl chloride spray prior to insertion of a contraceptive implant
Study: NCT04228523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic education workshop
Description: Workshop on Parkinson disease drug has several educative sequences (lasting 4hours).~* A first round table is organized to know the needs and issues related to drug management of patients.~* The 1st educative sequence consists in knowing the different class of dopaminergic drugs and their action.~* The 2nd educative sequence leads patients to understand their prescription and be aware of the needs to take pills regularly.~* The 3rd educative sequence consists in learning and identifying potentials adverse effects and finds effective strategies to prevent them.~At the end, one patient explains its tips and tricks about its drug management

Intervention type: OTHER
Group type: OTHER
Intervention: Speaking Therapy
Description: Speaking group is leaded by a psychologist from Centre Expert Parkinson (lasting 2 hours). This specific time is an exchange between patients with Parkinson disease who feel free to come. It is about sharing its own experience. It is a very special moment, confidential and kindly where patients don't judge themselves and speak only if they want to.
Study: NCT02170623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule I
Description: 25 mg BIBR 1048 MS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule K
Description: 50 mg BIBR 1048 MS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule K
Description: 50 mg BIBR 1048 MS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 40 mg pantoprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS drinking solution
Description: 50 mg BIBR 1048 MS powder plus solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS drinking solution
Description: 50 mg BIBR 1048 MS powder plus solution
Study: NCT04379856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM-002
Description: NM-002 is a fusion protein, of which the pharmacological active portion is the glucagon-like peptide-1 (GLP-1) analog domain with the same amino acid sequence as the active pharmaceutical ingredient (exenatide)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM-002
Description: NM-002 is a fusion protein, of which the pharmacological active portion is the glucagon-like peptide-1 (GLP-1) analog domain with the same amino acid sequence as the active pharmaceutical ingredient (exenatide)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM-002
Description: NM-002 is a fusion protein, of which the pharmacological active portion is the glucagon-like peptide-1 (GLP-1) analog domain with the same amino acid sequence as the active pharmaceutical ingredient (exenatide)
Study: NCT05771987

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pace maker implant guided by acute hemodynamic testing
Description: To evaluate the ability of acute hemodynamic testing to optimize pacing therapy and to predict the response of HOCM to pacing
Study: NCT02642185

Intervention type: PROCEDURE
Intervention: Microwave ablation
Description: CT-guided percutaneous ablation of 1-5, \<31mm in diameter, colorectal liver metastases, performed with any generic microwave ablation system cleared for clinical use

Intervention type: PROCEDURE
Intervention: Resection
Description: Open or laparoscopic resection of liver metastases using standard of care surgical procedures
Study: NCT05100550

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc is given as written in the arm description, two hours after lunch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This group will not receive zinc
Study: NCT04166422

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation program
Description: Aerobic treatment plus strength exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental intervention
Description: Aerobic treatment plus strengh exercises plus virtual reality
Study: NCT00587314

Intervention type: OTHER
Intervention: Biopsy
Description: Biopsies for research purposes will be obtained when returning for clinically indicated surveillance of Barrett's Esophagus
Study: NCT00853307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib capsules
Study: NCT03040544

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LTB-Curriculum
Description: The Lübeck Toolbox (LTB) curriculum has a structured training program, in which the laparoscopic basic skills are to be learned in six consecutive exercises. In doing so, the curriculum has precise targets for each of the six exercises based on the abilities of 15 MIS experts as a benchmark. The LTB curriculum is thus a structured training program with clear objectives that enable the technical learning of MIS basic skills comparable to the expert level.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Performing Laparoscopic cholecystectomy by surgical residents without previous experience in MIS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Performing Laparoscopic cholecystectomy by surgical residents without previous experience in MIS
Study: NCT02135432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04681443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystallized phenol application
Description: Crystallized phenol application into the sinus tract

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystallized phenol application
Description: Crystallized phenol application into the sinus tract
Study: NCT00667199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (BAY88-8223)
Description: The required volume of study drug to be administered to a patient was calculated using the patient's body weight, the dose (5 , 25 , 50 or 100 kBq/kg b.w.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (BAY88-8223)
Description: The required volume of study drug to be administered to a patient was calculated using the patient's body weight, the dose (5 , 25 , 50 or 100 kBq/kg b.w.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (BAY88-8223)
Description: The required volume of study drug to be administered to a patient was calculated using the patient's body weight, the dose (5 , 25 , 50 or 100 kBq/kg b.w.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (BAY88-8223)
Description: The required volume of study drug to be administered to a patient was calculated using the patient's body weight, the dose (5 , 25 , 50 or 100 kBq/kg b.w.)
Study: NCT00643747

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tgAAG76 (rAAV 2/2.hRPE65p.hRPE65)
Description: Single subretinal injection of vector suspension; up to 3x10e12 vector particles
Study: NCT04155762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pin Suspension System (a prosthetic suspension system)
Description: Participants used the PSS for three months following fabrication and adjustment of the prosthesis, and a prosthetic training period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vacuum-Assisted Suspension System (a prosthetic suspension system)
Description: After PSS, participants employed the VASS for three months after a similar training period.
Study: NCT00080535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMB-2
Description: 30 micrograms/kg every other day (QOD) x 3 every 4 weeks
Study: NCT01002339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus with rapid steroid withdrawal
Description: * Basiliximab induction (4 mg i.v., days 0 and 4).~* Corticosteroids: 0.5 gr of i.v. Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7.~* Tacrolimus: 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus with steroids minimization
Description: * Basiliximab induction (4 mg i.v., days 0 an 4)~* Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~* Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA with steroid minimization
Description: * Basiliximab induction (4 mg i.v., days 0 an 4)~* Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~* CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month and then 100-150 ng/ml.~* Mycophenolate mofetil 1 gr b.i.d
Study: NCT04369573

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Early intra-aortic balloon pump (IABP) implantation
Description: IABP implantation within 6 hours since cardiogenic shock symptoms onset

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care as vasoactive agent
Description: Any agent (inotropes and vasopressors) will be allowed. However, the following guide is provided to increase uniformity: 1) vasopressors allowed will be either epinephrine or norepinephrine; 2) as inotropic agent milrinone or dobutamine or levosimendan could be used; 3) dopamine will be allowed in association with milrinone or dobutamine or levosimendan; 4) the maximum inotropic score allowed will be 20.
Study: NCT00807911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant FL
Description: 5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant FOLFOX
Description: oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-Fluorouracil bolus 400 mg/m2 on D1, 5-Fluorouracil continuous infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles
Study: NCT03207971

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root coverage treatment with subepithelial connective tissue graft
Description: Periodontal plastic surgery aiming root coverage by palatal tissue graft removed from an area with predominance of lamina propria and predominance of submucosa.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root coverage treatment with subepithelial connective tissue graft
Description: Periodontal plastic surgery aiming root coverage by palatal tissue graft removed from an area with predominance of lamina propria and predominance of submucosa.
Study: NCT01253278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2393910
Description: as capsules, administered orally once daily for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2393910
Description: as capsules, administered orally once daily for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2393910
Description: as capsules, administered orally once daily for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2393910
Description: as capsules, administered orally once daily for two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: as capsules, administered orally once daily for two weeks
Study: NCT03557294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0mg Varenicline b.i.d.
Description: Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5mg Varenicline b.i.d.
Description: Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.0mg placebo Varenicline b.i.d.
Description: Product that looks like active varenicline, but contains no active ingredient
Study: NCT01510483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obesity Prevention
Description: Those in the experimental, obesity prevention, condition will be exposed to the office-wide intervention for diet and activity. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
Study: NCT02442492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
Study: NCT00418626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study: NCT02002650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-ERCP rectal Indomethacin
Description: Rectal Indomethacin was administrated within 30min before ERCP in all patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-operational Rectal Indomethacin
Description: Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
Study: NCT01510483

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Prevention
Description: Those in the control, tobacco prevention, condition will be exposed to the office-wide intervention for avoidance of tobacco and second hand smoke. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
Study: NCT03531970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine
Description: Anesthetic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2% lidocaine with 1:80,000 epinephrine
Description: Anesthetic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Corticostroide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00552877

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (Xience V stent)
Description: Cypher Select plus coronary stent Xience V coronary stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (Xience V stent)
Description: Cypher Select plus coronary stent Xience V coronary stent